AIFF — Firefly Neuroscience Income Statement
0.000.00%
- $37.19m
- $36.08m
- $0.11m
Annual income statement for Firefly Neuroscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 13.9 | 15 | 11 | 7.98 | 0.108 |
Cost of Revenue | |||||
Gross Profit | 2.21 | 3.62 | 2.86 | 2.61 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 13.5 | 17.2 | 16.4 | 9.77 | 10.2 |
Operating Profit | 0.412 | -2.18 | -5.42 | -1.79 | -10.1 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.413 | -2.2 | -5.49 | -1.5 | -10.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.413 | -1.13 | -6.31 | -1.45 | -10.5 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 0.413 | -1.13 | -17.8 | -2.03 | -10.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.413 | -1.13 | -17.8 | -2.03 | -10.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.03 | -2.23 | -9.71 | -3.34 | -1.51 |